Takeda Pharmaceutical Company Limited (TAK) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Honjutsu wa taihen o isogashii naka, Takeda Yakuhin Kogyo. Thank you for taking time out of your very busy schedule to join our earnings announcement for FY24 for Takeda. I'm the Master of Ceremony, Head of IR. My name is O'Reilly. Thank you for this opportunity. And allow me to explain about the language setting first. Please find the button for language selection at the bottom of your Zoom window. If you wish to listen in Japanese, please select Japanese. If you wish to listen in English, please select the English channel. If you want to listen to the original, please turn it off. For those of you who wish to listen to this call in English, please select English in the Zoom language select button. Before starting, I'd like to remind everyone that we'll be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those discussed today. The factors that could cause our actual results to differ materially are discussed in our most recent Form 20F and our other SEC filings. Please also refer to the important notice on page 2 of the presentation regarding forward-looking statements and our non-IFRS financial measures which will also be discussed during this call. Definitions of non-IFRS measures and reconciliation with comparative IFRS financial measures are included in the appendix in the presentation. Please also refer to page 2 for important reference. Moving on to today's presentation, today we have President and CEO Christoph Weber, Chief Financial Officer Mirana Furuta, President R&D Andy Plump presenting to you today. and this will be followed by question and answer. Let us get started. Christophe, over to you. Thank you, Chris, and thank you everyone for joining us ...